Meningeal dissemination in primary CNS lymphoma: Diagnosis, treatment, and survival in a large monocenter cohort

Neuro-Oncology

Volumn 12, Issue 4, 2010, Pages 409-417

  Kiewe, Philipp ^a   Fischer, Lars ^a   Martus, Peter ^a   Thiel, Eckhard ^a   Korfel, Agnieszka ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cerebrospinal fluid; CNS lymphoma; Meningeal dissemination; Prognosis

Indexed keywords

CARMUSTINE; DEXAMETHASONE; GADOLINIUM PENTETATE; IFOSFAMIDE; IMMUNOGLOBULIN HEAVY CHAIN; METHOTREXATE; PROCARBAZINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN BIOPSY; BRAIN LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL STRUCTURE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE REARRANGEMENT; HUMAN; IMMUNOCOMPETENCE; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOPHENOTYPING; INTRAOCULAR TUMOR; MAJOR CLINICAL STUDY; MALE; MENINGEAL BIOPSY; MENINGEAL METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; RETROSPECTIVE STUDY; SLIT LAMP; TREATMENT RESPONSE; CANCER STAGING; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; MENINGIOMA; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NONHODGKIN LYMPHOMA; PATHOLOGY; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954626089     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop053     Document Type: Article

References (39)

1. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21:1044-1049.
2. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266-272.
3. Jahnke K, Korfel A, Martus P, et al.; on the behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG). High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol. 2005;16:445-449. (Pubitemid 40458322)
4. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82:733-739.
5. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38:51-57.
6. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29:1369-1375.
7. Balmaceda C, Gaynor JJ, Sun M, Gluck JT, DeAngelis LM. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol. 1995;38:202-209.
8. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol. 1999;43: 237-239.
9. Cartmill M, Allibone R, Bessell EM, Byrne PO. Primary cerebral non-Hodgkin's lymphoma: problems with diagnosis and development of a protocol for management. Br J Neurosurg. 2000;14:313-315.
10. Haldorsen IS, Espeland A, Larsen JL, Mella O. Diagnostic delay in primary central nervous system lymphoma. Acta Oncol. 2005;44:728-734.
11. Pels H, Juergens A, Glasmacher A, et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol. 2009;91:299-305.
12. Pels H, Schmidt-Wolf IGH, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489-4495. (Pubitemid 46594018)
13. Sandor V, Stark-Vancs V, Pearson D, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol. 1998;16:3000-3006.
14. Korfel A, Martus P, Nowrousian MR, et al.; German primary central nervous system lymphoma Study Group (G-PCNSL-SG). Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br J Haematol. 2005;128: 177-183.
15. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer. 2008;112, 1812-1820.
16. Kranz BR, Thiel E, Thierfelder S. Immunocytochemical identification of meningeal leukemia and lymphoma: poly-L-lysine-coated slides permit multimarker analysis even with minute cerebrospinal fluid cell specimens. Blood. 1989;73:1942-1950.
17. Gleissner B, Siehl J, Korfel A, Reinhardt R, Thiel E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology. 2002;58:390-396.
18. Galoin S, Daste G, Apoil PA, et al. Polymerase chain reaction on cerebrospinal fluid cells in the detection of leptomeningeal involvement by B-cell lymphoma and leukaemia: a novel strategy and its implications. Br J Haematol. 1997;99:122-130.
19. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-2317.
20. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711-5715.
21. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244 (Erratum in: J Clin Oncol 2000;18:2351).
22. Finn WG, Peterson LC, James C, Goolsby CL. Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry. Am J Clin Pathol. 1998;110:341-346.
23. French CA, Dorfman DM, Shaheen G, Cibas ES. Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis. Diagn Cytopathol. 2000;23: 369-374.
24. Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007;68;1674-1679.
25. Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105:496-502.
26. Montesinos-Rongen M, Küppers R, Schlüter D, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol. 1999;155:2077-2086.
27. Thompsett AR, Ellison DW, Stevenson FK, Zhu D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood. 1999;94:1738-1746.
28. Fischer L, Martus P,Weller M, et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology. 2008;71:1102-1108.
29. Ekstein D, Ben Yehuda D, Slyusarevsky E, Lossos A, Linetsky E, Siegal T. CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course. J Neurol Sci. 2006;247:39-46.
30. Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-Mönting J, Behringer DM. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis-a single centre experience. Br J Haematol. 2004;124, 762-768.
31. Kuker W, Nagele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72:169-177. (Pubitemid 40796468)
32. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16:864-871.
33. Fischer L, Jahnke K, Martus P, Weller M, Thiel E, Korfel A. The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. Haematologica. 2006;91:429-430.
34. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ; Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20:4643-4648.
35. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24:4570-4574.
36. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18:3144-3150.
37. Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21:2726-2731.
38. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. European Organization for Research and Treatment of Cancer Lymphoma Group. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21:4483-4488.
39. O'Brien P, Roos D, Pratt G, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000;18:519-526.